The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.
Epicardial adipose tissue in contemporary cardiology
Open accessAbstract
Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and unobstructed proximity to the heart and has a transcriptome and secretome very different from that of other fat depots. EAT has physiological and pathological properties that vary depending on its location. It can be highly protective for the adjacent myocardium through dynamic brown fat-like thermogenic function and harmful via paracrine or vasocrine secretion of pro-inflammatory and profibrotic cytokines. EAT is a modifiable risk factor that can be assessed with traditional and novel imaging techniques. Coronary and left atrial EAT are involved in the pathogenesis of coronary artery disease and atrial fibrillation, respectively, and it also contributes to the development and progression of heart failure. In addition, EAT might have a role in coronavirus disease 2019 (COVID-19)-related cardiac syndrome. EAT is a reliable potential therapeutic target for drugs with cardiovascular benefits such as glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter 2 inhibitors. This Review provides a comprehensive and up-to-date overview of the role of EAT in cardiovascular disease and highlights the translational nature of EAT research and its applications in contemporary cardiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Visceral adiposity in particular has been causally implicated in adverse cardiovascular outcomes via the release of proinflammatory cytokines.6”
From Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Paracardiac adipose tissue has been hypothesized to act in a paracrine manner, with release of proinflammatory and profibrotic adipocytokines and excess free fatty acids with resultant intramyocardial lipid accumulation and myocardial inflammation and fibrosis.19”
From Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,532
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
COVID-19 and the cardiovascular system
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0360-5 · Cited by 2,970
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,228
Cited by
Sorted by citations
Items 801–812 of 812
Epicardial fat inflammation: bridging adipose tissue biology and cardiovascular medicine
Iacobellis, G. (2026) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2026.10.008
Self-citationObesity and Atrial Fibrillation: Weighing the Evidence
Ha, F. J., Tang, J. Y., Khanna, S., Brown, A. J., Kotschet, E., & Nerlekar, N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208101
Convergent ferroptosis and pyroptosis in MASLD-associated cardiac remodeling
Gui, H., Yuan, X., & Zhang, Y. (2026) · Translational research · doi:10.1016/j.trsl.2026.10.007
Aslan, A. N., & Özbebek, Y. E. (2026) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.6389
Nzobokela, J., Choolwe, S. C., & Masenga, S. K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1987811
Fukushima, T., Yanagisawa, S., Miyazawa, H., Tanaka, Y., Kitahara, T., Hiramatsu, S., Hiramatsu, T., Adachi, K., Teraoka, T., Ota, R., et al. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.10.045
Pichon, M., Alos, B., Levesque, S., Bochaton, T., Havard, A., Beard, E., Patouiller, V., Ramonatxo, A., Chong-Nguyen, C., Pin, M., et al. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100996
An α1D-adrenergic receptor vaccine protects against HFpEF in mice
Wu, J., Shi, D., Wang, Y., Ma, Q., Chen, H., Huang, J., Ma, W., Lama, E., Liu, C., Gao, R., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117604
Metaflammation: linking diet and obesity to multiorgan dysfunction
Vieira, T. A., Cruzeiro, J., Grandini, N. A., Tanganini, M. D., dos Santos, M. D. P. S., Belin, M. A. F., Francisqueti‐Ferron, F. V., Ferron, A. J. T., & Corrêa, C. R. (2026) · Nutrire · doi:10.1186/s41110-026-00558-0
Harada, T., Kondo, H., & Takahashi, N. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag234
Steffen, H. J., Behnes, M., Weidner, K., Langer, H. F., Akin, I., & Schupp, T. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103294
Tabatabaei, S. A. D., & Tabatabaei, M. D. (2026) · Clinical Cardiology · doi:10.1002/clc.70509
Metadata
- Authors
- Iacobellis, G.
- Affiliations
- University of Miami (US)
- Corresponding author
- Iacobellis, Gianluca
- ORCID
- Iacobellis, Gianluca
- Venue
- Nature Reviews Cardiology
- Published
- 2022-03-16
- Volume
- 19
- Issue
- 9
- Pages
- 593-606
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC8926097
- OpenAlex
- W4220961850
- Cited by
- 797
- References
- 161
- Citations by year
- 2026: 195 · 2025: 236 · 2024: 214 · 2023: 118 · 2022: 32
- FWCI
- 31.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- epicardial adipose tissue, coronary artery disease, atrial fibrillation, heart failure, brown fat thermogenesis, inflammatory cytokines, profibrotic cytokines, GLP-1 receptor agonists, SGLT2 inhibitors, cardiovascular risk factors
- MeSH terms
- COVID-19, Adipose Tissue, Atrial Fibrillation, Cardiology, Humans, Pericardium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
